Anti-epidermal growth factor receptor (anti-EGFR) agents as adjuncts to conventional treatment for head and neck squamous cell carcinomas

To determine the efficacy and safety of the addition of anti-EGFR therapy to conventional treatments in patients with locoregionally advanced, recurrent or metastatic mucosal head and neck squamous cell carcinoma.

This is a protocol.